Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2021	$ 6	$ 689,866		$ (308,126)	$ 381,746
Beginning balance, shares at Dec. 31, 2021	56,969,618
Issuance of common stock upon exercise of stock options		102			102
Issuance of common stock upon exercise of stock options, shares	21,787
Vesting of restricted common stock, shares	12,723
Stock-based compensation expense		6,066			6,066
Net loss				(34,999)	(34,999)
Ending balance at Mar. 31, 2022	$ 6	696,034		(343,125)	352,915
Ending balance, shares at Mar. 31, 2022	57,004,128
Beginning balance at Dec. 31, 2022	$ 6	727,335	$ (83)	(444,765)	282,493
Beginning balance, shares at Dec. 31, 2022	59,505,437
Issuance of common stock in connection with the Moderna Agreement	$ 1	22,555			22,556
Issuance of common stock in connection with the Moderna Agreement, shares	5,859,375
Vesting of restricted common stock		(199)			(199)
Vesting of restricted common stock, shares	170,851
Stock-based compensation expense		6,266			6,266
Unrealized losses on marketable securities			117		117
Net loss				(32,094)	(32,094)
Ending balance at Mar. 31, 2023	$ 7	$ 755,957	$ 34	$ (476,859)	$ 279,139
Ending balance, shares at Mar. 31, 2023	65,535,663